Clinical trial
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung…
NCT00087412 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00087412 |
|---|---|
| Title | S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer |
| Official title | Phase II Trial of OSI-774 (NSC-718781) in Patients With Advanced Non-Small Cell Lung Cancer and a Performance Status of 2 |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Lung, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer |
| Intervention type | Drug, Other |
| Interventions | erlotinib hydrochloride, laboratory biomarker analysis |
| Enrollment | 65 |
| Start date | Sep 1, 2004 |
| Primary completion | Jul 1, 2007 |
| First posted | Jul 12, 2004 |
| Last update posted | Feb 28, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: